NeuroTrac Continence

NeuroTrac Continence

Brand: NeuroTrac
SKU: neurotrac-continence
111.99 GBP In stock Buy at Merchant

Electrical stimulation device for pelvic floor rehabilitation and continence management UKCA marked Class IIa medical device Suitable for men and women The NeuroTrac Continence is a single-channel neuromuscular electrical stimulation (NMES) device designed for pelvic floor retraining and continence management at home. It delivers symmetrical, rectangular biphasic constant current to stimulate pelvic floor muscles and nerve fibres, making it suitable for stress, urge, and mixed urinary incontinence, as well as pelvic floor pain and muscle weakness. Compatible with vaginal probes, anal probes, and skin-surface electrodes, it is suitable for both men and women. Nine preset continence programmes cover the most common clinical presentations, with customisable programmes available for more tailored treatment. It is recommended for use under the guidance of a physiotherapist or suitably qualified clinician. Key features Channels Single channel Output type Constant current, symmetrical biphasic Amplitude 0–90 mA (into 500 Ohm load) Pulse width 50–330 μS (±2% accuracy) Pulse rate 2–100 Hz (±2% accuracy) Preset programmes 9 continence programmes Custom programmes 3 fully adjustable programmes Session duration 1–90 minutes, selectable Power 9V alkaline battery (PP3) In the box NeuroTrac Continence unit, 9V alkaline battery, lead wire, and quick-start instructions. Probes and electrodes are not included and must be purchased separately. Important: The NeuroTrac Continence is a UKCA-marked Class IIa medical device. It is intended for use under the guidance of a physiotherapist or qualified clinician. If you are unsure whether this device is appropriate for your condition, please consult your GP or a pelvic health physiotherapist before purchase so they can show you how to use it.

Specifications
VAT
VAT Exempt, VAT Included
Variants (2)
  • VAT Exempt — 111.99 GBP — In stock
  • VAT Included — 134.39 GBP — In stock

AI Readiness

Good foundation, but some important product data is still missing.

78%